Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study

Low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Information regarding demographic characteristics, clinical comorbidities, ASCVD history, LLT use at baseline, pre- and post-treatment cholesterol levels, evolocumab-related side effects, and evolocumab compliance and adherence was obtained from the patients’ medical records or telephone consultation. See PDF] The overall percentages of patients who achieved an LDL-C goal of